Agmatine is a metabolite of L-arginine that modulates multiple neurotransmitter systems (NMDA, imidazoline, alpha-2 adrenergic) and nitric oxide pathways. Preliminary human trials show it reduced neuropathic pain by 46% at doses of 1,330-3,560mg/day over 2 weeks. Our research identifies it as one of the most pharmacologically complex supplements available — its multi-receptor activity means drug interaction screening is essential.
Agmatine acts on at least four receptor systems simultaneously: it blocks NMDA glutamate receptors (reducing excitotoxicity and pain), activates imidazoline receptors (lowering blood pressure and modulating insulin), stimulates alpha-2 adrenergic receptors (pain modulation), and inhibits nitric oxide synthase (NOS) — but selectively. It inhibits iNOS (inflammatory NO) while preserving eNOS (vascular NO), which is why it can reduce inflammation without impairing blood flow.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.